BioSpace News Archive

Xencor, Inc. announced that John J. Kuch, senior vice president and chief financial officer, plans to retire in March 2024, after a 23-year career with Xencor and over 40 years in corporate finance.

Medidata today announced a multi-year partnership expansion with Catalyst Clinical Research to support their global oncology brand, Catalyst Oncology.

Sandoz, the global leader in generic and biosimilar medicines, announced the issuance of two highly successful inaugural CHF bonds with gross proceeds of CHF 750 million.

As part of the U.S. Food and Drug Administration’s commitment to protecting public health, the agency is advising the public, including healthcare providers, of the possible risks that products containing live bacteria or yeast, which are commonly called probiotics, pose to preterm infants in hospital settings.

Fore Genomics, Inc. announced the launch of its revolutionary FORESITE 360™ service using whole genome sequencing , which gives you a complete map of your baby’s DNA with a simple at-home collection kit.

PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General Psychiatry, an internationally recognized scientific psychiatry publication, has accepted the manuscript titled “Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder” for publication.

Aurinia welcomes the 2023 updated recommendations from The European Alliance of Associations for Rheumatology for the management of systemic lupus erythematosus based on emerging new evidence, including a new treatment paradigm for lupus nephritis.

Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported that Santhera Pharmaceuticals (“Santhera”) has obtained U.S. Food and Drug Administration (“FDA”) approval for AGAMREE® (vamorolone) oral suspension 40 mg/mL for use in treating Duchenne Muscular Dystrophy (“DMD”) in patients aged two years and older.

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2023 financial results after the close of U.S. financial markets on Thursday, November 2, 2023.